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Abstract. 
 
The release of biogenic amines from large
dense core vesicles (LDCVs) depends on localization
of the vesicular monoamine transporter VMAT2 to
LDCVs. We now ﬁnd that a cluster of acidic residues
including two serines phosphorylated by casein kinase
2 is required for the localization of VMAT2 to LDCVs.
Deletion of the acidic cluster promotes the removal of
VMAT2 from LDCVs during their maturation. The
 
motif thus acts as a signal for retention on LDCVs.
In addition, replacement of the serines by glutamate
to mimic phosphorylation promotes the removal of
VMAT2 from LDCVs, whereas replacement by alanine
to prevent phosphorylation decreases removal. Phos-
phorylation of the acidic cluster thus appears to reduce
the localization of VMAT2 to LDCVs by inactivating a
retention mechanism.
Key words: acidic cluster • large dense core vesicles •
phosphorylation • VMAT2 • furin
 
Introduction
 
Neurotransmitter release involves the regulated exocyto-
sis of multiple, distinct types of secretory vesicle including
 
synaptic vesicles (SVs)
 
1
 
 and large dense core vesicles
(LDCVs). Although SVs and LDCVs both undergo regu-
lated exocytosis, they differ in the site and mode of re-
lease, as well as in their contents. SVs cluster at the nerve
terminal, mediate the rapid release of neurotransmitter
into the synaptic cleft, and store classical neurotransmitter
(Sudhof, 1995; Calakos and Scheller, 1996). In contrast,
LDCVs appear in dendrites as well as axons, release their
contents more slowly and in response to different stimuli
than SVs, and contain neuromodulatory peptides, growth
factors, and certain classical transmitters such as monoam-
ines (De Camilli and Jahn, 1990; Martin, 1994). SVs and
LDCVs also differ in their biogenesis. SVs form locally at
the nerve terminal, whereas LDCVs bud directly from the
trans-Golgi network (Kelly and Grote, 1993; Tooze et al.,
1993). Differences in protein sorting at these sites presum-
ably underlie the differences in protein composition and
hence vesicle function. However, little is known about the
cellular mechanisms that target proteins to different
classes of neurosecretory vesicles. To identify the signals
that target proteins to SVs and LDCVs, we have focused
on a family of membrane proteins required for the exocy-
totic release of neurotransmitter.
Classical transmitters are synthesized in the cytoplasm
and require packaging into secretory vesicles by specific
transport proteins. The localization of these proteins to
SVs, LDCVs, or other types of neurosecretory vesicle de-
termines the site of neurotransmitter storage and hence
the mode of release. Dopamine in particular undergoes re-
lease from the cell body and dendrites of midbrain dopa-
mine neurons as well as from nerve terminals in the stria-
tum (Geffen et al., 1976; Cheramy et al., 1981; Robertson et
al., 1991; Heeringa and Abercrombie, 1995; Jaffe et al., 1998),
and somatodendritic release has been proposed to regulate
neuronal activity (Aghajanian and Bunney, 1974; Grace
and Bunney, 1995). Consistent with the release of dopam-
ine at these sites, the vesicular monoamine transporter
(VMAT2) responsible for dopamine transport into secre-
tory vesicles resides on LDCVs and tubulovesicular struc-
tures in the cell body and dendrites as well as on SVs at the
nerve terminal (Weihe et al., 1994; Nirenberg et al., 1995,
1996, 1997; Peter et al., 1995). Studies of leech Retzius neu-
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rons further support the release of serotonin from both
LDCVs located in the cell body and terminal and from SVs
restricted to the terminal (Bruns and Jahn, 1995). Since the
localization of VMAT2 to LDCVs influences the site and
mode of monoamine release, the expression of VMAT2 on
LDCVs presumably contributes to the role of dopamine,
norepinephrine, and serotonin in neuromodulation.
As an integral membrane protein, VMAT2 must also
contain signals that direct its trafficking to LDCVs
(Krantz et al., 2000). To identify the signals responsible for
the membrane trafficking of VMAT2, we have used heter-
ologous expression in PC12 cells, where VMAT2 targets
preferentially to LDCVs (Liu et al., 1994; Varoqui and
Erickson, 1998; Krantz et al., 2000). We previously identi-
fied a dileucine-like motif in the cytoplasmic COOH ter-
minus of VMAT2 that mediates internalization from the
plasma membrane (Tan et al., 1998). The closely related
vesicular acetylcholine transporter (VAChT) contains a
very similar motif, but unlike VMAT2, VAChT targets
preferentially to synaptic-like microvesicles (SLMVs)
rather than LDCVs in PC12 cells (Liu and Edwards, 1997;
Varoqui and Erickson, 1998). VMAT2 also differs from
VAChT 4 and 5 residues upstream of the dileucine-like
signal, positions shown to be important for the trafficking
of other proteins (Pond et al., 1995; Dietrich et al., 1997).
Although these residues do not affect the endocytosis of
either VMAT2 or VAChT (Tan et al., 1998), we have re-
cently found that they influence targeting to LDCVs and
account in part for the observed differences in steady state
localization between these two transport proteins (Krantz
et al., 2000).
The analysis of COOH-terminal deletions in VMAT2
now implicates an acidic motif containing two serines
phosphorylated by casein kinase 2 (CK2; Krantz et al.,
1997) in targeting to LDCVs. After budding from the
TGN, LDCVs undergo a maturation process in which pro-
teins destined for other compartments such as lysosomes
are removed (Tooze et al., 1993; Kuliawat et al., 1997;
Klumperman et al., 1998). Deletion of the COOH-termi-
nal acidic motif reduces the expression of VMAT2 on
LDCVs by promoting its removal during LDCV matura-
tion. The motif thus appears to act as a signal for retention
on LDCVs. Interestingly, the TGN endoprotease furin
contains a similar acidic cluster with two serines phos-
phorylated by CK2. Phosphorylation of this motif in-
creases furin retrieval from LDCVs (Jones et al., 1995;
Dittie et al., 1997), apparently through an interaction with
the novel cytosolic adaptor protein PACS-1 (phosphofurin
acidic cluster sorting protein 1) (Wan et al., 1998). In
VMAT2, replacement of serines in the acidic motif by
aspartate to mimic phosphorylation also promotes the
removal of VMAT2 during LDCV maturation, whereas
replacement by alanine to prevent phosphorylation in-
creases localization to LDCVs. Phosphorylation thus
appears to promote VMAT2 retrieval from immature
LDCVs by blocking the role of the acidic motif in reten-
tion. Very similar to furin, the phosphorylated form of the
acidic cluster in VMAT2 also binds to PACS-1. Despite
the similarities between VMAT2 and furin, however,
VMAT2 normally resides in LDCVs, whereas furin local-
izes to the TGN (Liu and Edwards, 1997; Krantz et al.,
2000). Differences in phosphorylation state presumably
account for the divergent steady state location of these
proteins by influencing their removal from LDCVs.
 
Materials and Methods
 
Antibodies 
 
Mouse monoclonal HA.11 antibody was obtained from Covance, the rat
monoclonal hemagglutinin (HA) antibody from Boehringer, the rabbit
polyclonal antiserum to secretogranin II from BioDesign, the mouse mono-
clonal antibody to the transferrin receptor from Zymed, the rabbit poly-
clonal antiserum to rab5 from Quality Controlled Biochemicals, the mouse
monoclonal antibody to 
 
g
 
-adaptin from Transduction Laboratories, the
rabbit polyclonal antibody to synaptophysin from Zymed, and the mouse
monoclonal anti–his and goat polyclonal anti–glutathione-S-transferase
(GST) antibodies from Amersham Pharmacia Biotech. Secondary antibod-
ies conjugated to FITC, Texas red, Cy3, and Cy5 were obtained from Jack-
son ImmunoResearch Laboratories, and secondary antibodies conjugated
to horseradish peroxidase from Amersham Pharmacia Biotech (anti–rabbit
and anti–mouse) or Sigma-Aldrich (anti–goat). Brefeldin A was obtained
from Epicentre Technologies. Drs. F. Brodsky and K. Mostov (University
of California at San Francisco, San Francisco, CA) generously provided an-
tibodies to TGN-38 and mannose-6-phosphate receptor, respectively.
 
Mutagenesis, Cell Culture, and Immunofluorescence
 
Mutagenesis was performed using the Kunkel method (Kunkel et al.,
1991). PC12 cells were transfected by electroporation, and independent
cell clones were isolated as previously described (Krantz et al., 2000). Af-
ter plating onto glass coverslips coated with poly-
 
L
 
-lysine and Matrigel
(Becton Dickinson) and treatment with 50 ng/ml NGF for 2–3 d, the cells
were immunostained as previously described (Tan et al., 1998) and visual-
ized by confocal laser microscopy. For the experiments with brefeldin A
(BFA), the cells were incubated with 5 
 
m
 
g/ml BFA in standard medium
for 15 min at 37
 
8
 
C before fixation.
 
Density Gradient Fractionation
 
PC12 cells were rinsed with cmf-PBS, harvested in 0.3 M sucrose, 10 mM
Hepes, pH 7.4 (sucrose-Hepes buffer) containing 2 mM Mg EGTA, 1 
 
m
 
g/
ml leupeptin, 1 
 
m
 
g/ml pepstatin, and 10 
 
m
 
g/ml PMSF, and the cells were
disrupted at a clearance of 10 
 
m
 
m in a ball-bearing homogenizer. After
pelleting the nuclei at 1000 
 
g
 
 for 8 min, the resulting post-nuclear superna-
tant (PNS) was layered onto a linear 0.6–1.6 M sucrose gradient and sedi-
mented to equilibrium at 30,000 rpm for 12–16 h in an SW41 rotor at 4
 
8
 
C.
Fractions were collected from the top.
 
Velocity Gradient Sedimentation
 
Metabolic labeling with 
 
35
 
S-sulfate was done as done previously described
(Tooze and Huttner, 1990; Dittie et al., 1996). In brief, PC12 cells were
rinsed twice with sulfate-free medium, incubated at 37
 
8
 
C for 30 min, and
then labeled for 5 min in the same medium containing 0.5 mCi/ml 
 
35
 
S-sul-
fate (NEN Life Science Products). To label secretogranin II (SgII) in the
TGN, the cells were chilled and harvested. To allow labeled SgII to enter
iLDCVs, the labeled cells were incubated at 37
 
8
 
C for an additional 15 min
in standard PC12 medium containing sulfate. To allow the passage of la-
beled SgII into mature LDCVs, cells were incubated for 6 h with 0.2 mCi/
ml 
 
35
 
S-sulfate in sulfate-free medium, and then for 12–16 h in standard
PC12 medium.
Gradients were performed according to established protocols (Dittie et
al., 1996; Blagoveshchenskaya et al., 1999). After labeling with 
 
35
 
S-sulfate,
cells were immediately placed on ice, rinsed with cold cmf-PBS containing
1 mM MgSO
 
4
 
, harvested in a modified sucrose-Hepes buffer (0.25 M su-
crose, 10 mM Hepes-KOH, pH 7.2) containing protease inhibitors, 1 mM
EGTA, and 1 mM MgSO
 
4
 
, the PNS prepared as above, layered onto a lin-
ear 0.3–1.2 M sucrose gradient in 10 mM Hepes-KOH, pH 7.2, and sedi-
mented for 19 min at 25,000 rpm in an SW41 rotor at 4
 
8
 
C.
To separate iLDCVs from mLDCVs, fractions from the velocity gradi-
ent that contained iLDCVs or mLDCVs were identified by scintillation
counting, pooled, diluted with 10 mM Hepes-KOH, pH 7.2, layered onto
linear 0.9–1.7 M sucrose gradients made in 10 mM Hepes-KOH, pH 7.2,
and sedimented for 21 h at 30,000 rpm in an SW41 rotor at 4
 
8
 
C. Fractions
were collected from the top.
 
Western Analysis and Quantitation
 
Proteins were separated by electrophoresis through SDS-polyacryl-
amide, electroblotted to PVDF or nitrocellulose, and immunostained as
previously described (Krantz et al., 2000). After detection of the bound
antibodies using SuperSignal West Pico substrate (Pierce Chemical 
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Co.), the films were optically scanned, digitized, and quantified using
NIH Image.
To quantify the one-step sucrose equilibrium gradients, the amount of
HA or SgII immunoreactivity in each gradient fraction was expressed as a
fraction of the total HA or SgII immunoreactivity in all gradient fractions.
For the two-step gradients, the sorting index for localization to i- or
mLDCVs was determined by first identifying the two peak iLDCV frac-
tions and the two peak mLDCV fractions through autoradiography for
 
35
 
S-sulfate–labeled SgII. The HA immunoreactivity in these peak frac-
tions was then measured by densitometry and used to calculate the pro-
portion of HA immunoreactivity in the two peak iLDCV fractions and the
two peak mLDCV fractions relative to the total HA immunoreactivity in
all four peak fractions.
 
Bacterial Expression and In Vitro Phosphorylation
 
COOH-terminal fragments of the wild-type, 507*, AA, and DD VMAT2
cDNAs were subcloned using EcoRV, inserted in-frame into the SmaI site
of pGEX-3X-1 (Amersham Pharmacia Biotech), and expressed as GST fu-
sion proteins in 
 
Escherichia coli
 
 as previously described (Krantz et al.,
2000). The furin-binding domain of PACS-1 subcloned into pET-16b
 
(Novagen) was also expressed and purified by Ni
 
2
 
1
 
 chromatography. To
phosphorylate the GST fusions, the proteins bound to glutathione-
sepharose beads were incubated in 20 mM Tris, pH 7.5, 50 mM KCl, 1 mM
DTT, and 10 mM MgCl
 
2 
 
(phosphorylation buffer) containing 200 
 
m
 
M ATP,
500 
 
m
 
Ci/
 
m
 
mol 
 
g
 
-
 
32
 
P-ATP, and 250 U casein kinase 2 for 90 min at 30
 
8
 
C,
washed twice in PBS with 15 mM EDTA, and tested for binding to PACS-1.
 
PACS-1 Binding Assay
 
Following a procedure described previously (Xiang et al., 2000), GST fu-
sion proteins were bound to glutathione-sepharose beads for a final con-
centration of 
 
z
 
5 
 
m
 
g/ml, incubated in 150 mM NaCl, 50 mM Tris, pH 7.5, 2
mM MgCl
 
2
 
, and 2% Triton X-100 (binding buffer) with 2.5 
 
m
 
g/ml purified
PACS-1 for 1 h at room temperature, washed three times in binding
buffer, and the proteins eluted with SDS sample buffer, separated by elec-
trophoresis, and transferred to PVDF. Phosphorylated GST fusions were
detected by autoradiography, and unlabeled GST fusions and bound
PACS-1 were detected by Western analysis using anti–GST and anti–His
antibodies, respectively. After autoradiography or detection of the bound
antibodies by ECL Plus (Amersham Pharmacia Biotech), the films were
optically scanned.
Figure 1. Analysis of COOH-
terminal VMAT2 deletions by
immunofluorescence. (A) Serial
deletions of the VMAT2 COOH
terminus were created by insert-
ing stop codons after residues
507, 491, and 484. *The position
of the inserted stop codon. (B)
PC12 cells stably expressing HA-
tagged wild-type VMAT2 or the
deletion mutants were double
stained with a mouse monoclonal
antibody to HA followed by anti–
mouse antibodies conjugated to
Cy3 (a, d, g, and j), and with a
polyclonal rabbit antiserum to
SgII followed by anti–rabbit anti-
bodies conjugated to Cy5 (b, e, h,
and k), and then examined by
confocal microscopy. Merged
Cy3 and Cy5 images are shown in
c, f, i, and l. Wild-type VMAT2
(a–c) colocalizes extensively with
SgII and appears primarily at the
tips of cell processes (arrows). In
contrast, the mutants show little
colocalization with SgII (d–l). All
exhibit reduced staining at the
tips of process and strong expres-
sion in the perinuclear region (ar-
rowheads). Bar, 10 mm. 
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Results
 
Deletion of an Acidic Motif Redistributes VMAT2 
Away from LDCVs
 
To identify signals that influence the subcellular location
of VMAT2, we expressed a series of COOH-terminal
truncations in PC12 cells, which produce both LDCVs and
SLMVs. These constructs contain an HA epitope in the lu-
menal loop between transmembrane domains 1 and 2, and
stop codons after residues 507, 491, and 484 (507*, 491*,
and 484*; Fig. 1 A). Using immunofluorescence to com-
pare the localization of the introduced VMAT2 with
secretogranin II, a soluble protein contained in LDCVs,
we found that wild-type VMAT2 colocalizes precisely with
SgII at the tips of processes (Fig. 1 B, a–c). Both proteins
are expressed at low levels in cell bodies. In contrast, the
deletion mutants colocalize poorly with SgII (Fig. 1 B, d–l).
These truncations exhibit a perinuclear staining pattern
with little expression at the tips of processes, indicating the
presence of a second trafficking motif at the COOH termi-
nus of VMAT2. The distribution of 507* strongly resem-
bles that of 491* and 484*, indicating that the last eight
amino acids of VMAT2 (DDEESESD) comprise a major
trafficking signal.
To confirm that deletion of the acidic cluster alters the
localization of VMAT2 in PC12 cells, we analyzed the
507* mutant by density gradient fractionation. Equilib-
rium sedimentation through sucrose, which separates
LDCVs from lighter membranes such as SLMVs and en-
dosomes, shows that wild-type VMAT2 colocalizes with
SgII in heavy, LDCV-containing fractions (Fig. 2 A), as
previously observed (Krantz et al., 2000). Only very small
amounts of VMAT2 appear in lighter fractions (Fig. 2 A).
In contrast, the 507* mutant colocalizes less well with SgII
in heavy fractions and is more prominent in lighter frac-
tions (Fig. 2 B). Equilibrium sedimentation thus confirms
the importance of a COOH-terminal acidic cluster for the
localization of VMAT2 to LDCVs.
By immunofluorescence, the 507* mutant localizes to a
perinuclear compartment. To identify this compartment,
we used double staining to assess the colocalization of
507* with markers for various intracellular membranes.
The 507* mutant does not colocalize with markers for the
endoplasmic reticulum (ribophorin II), cis-Golgi (
 
b
 
-COP),
or early endosomes (rab 5) (data not shown). The sucrose
density gradient suggested expression on lighter mem-
branes that might represent SLMVs (Fig. 2 B), but 507*
shows only partial colocalization with synaptophysin (Fig.
3, a–c). The perinuclear distribution of 507* resembles
that of the endosomal transferrin receptor, the late endo-
somal mannose 6 phosphate receptor (Fig. 3, d–i), and the
lysosomal cathepsin B (data not shown). However, the
merged images at higher magnification show only minor
colocalization. On the other hand, 507* colocalizes more
extensively with markers for the trans-Golgi network such
as the clathrin adaptor protein AP-1 (data not shown) and
TGN-38 (Fig. 3, j–l).
 
Localization of 507* to Immature LDCVs
 
To determine whether 507* localizes to the TGN or to
closely apposed membranes, we treated the stable PC12
transformants with brefeldin A, a fungal derivative that
causes fragmentation of the TGN. If expressed in the
TGN, 507* should redistribute to the cell periphery after
exposure to BFA. BFA indeed collapses TGN-38 as ex-
pected, but 507* remains largely perinuclear (Fig. 4 A).
Since immature LDCVs (iLDCVs) bud from the TGN and
may function as a specialized extension of this sorting
compartment, 507* might localize instead to iLDCVs. To
Figure 2. Density gradient fractionation of wild-type and 507*
VMAT2. Post-nuclear supernatants from PC12 cells stably ex-
pressing HA-tagged wild-type (A) and 507* (B) VMAT2 were
separated by equilibrium gradient centrifugation through 0.6–
1.6 M sucrose. Fractions were collected and analyzed by Western
blot using the monoclonal HA antibody to detect VMAT2 (A
and B, top), and a polyclonal antibody to detect the LDCV
marker SgII (bottom). The immunoblots were then digitized and
quantified using NIH Image. For each fraction, the amount of
VMAT2 and SgII is expressed as a percentage of total immunore-
activity in all the fractions. Wild-type VMAT2 cofractionates
with SgII in heavy fractions, whereas 507* cofractionates to a
lesser extent with SgII and appears instead in lighter fractions.
The analysis of three different stable cell lines for each construct
yielded similar results. 
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test this possibility, we used sulfate labeling of SgII to-
gether with gradient fractionation (Tooze and Huttner,
1990). Cells were labeled first for 5 min with 
 
35
 
S-sulfate,
which incorporates heavily into SgII as it transits the TGN,
and then either chilled on ice to prevent the exit of labeled
SgII from the TGN, or incubated at 37
 
8
 
C in medium with
unlabeled sulfate for an additional 15 min to allow passage
of the labeled SgII into iLDCVs. Chase for 15 min does
not allow sufficient time for LDCV maturation. We then
used velocity gradient fractionation to separate iLDCVs
from the TGN. Autoradiography showed the shift of SgII
from heavy to light fractions over the 15-min chase (Fig. 4
B), as expected. Western analysis showed that 507* colo-
calizes with the iLDCV-containing rather than the TGN-
containing fractions (Fig. 4 B). Thus, 507* may reside on
iLDCVs even though it is greatly reduced on the entire
population of LDCVs (Figs. 1 and 2).
The presence of 507* on iLDCVs despite a low propor-
tion on LDCVs raises the possibility that the mutant is re-
moved during LDCV maturation. To determine whether
507* indeed resides on iLDCVs, we again used the label-
ing of SgII with 
 
35
 
S-sulfate followed by gradient fraction-
ation (Dittie et al., 1997; Blagoveshchenskaya et al., 1999).
Labeling for 5 min followed by incubation for an addi-
tional 15 min with unlabeled sulfate allows the labeled
SgII to enter iLDCVs, but not mature LDCVs. Labeling
for 6 h followed by 12 h of chase allows sufficient time for
the maturation of LDCVs containing labeled SgII. To sep-
arate iLDCVs from mLDCVs, and hence determine the
fate of VMAT2 during LDCV maturation, we used se-
quential velocity and equilibrium sedimentation through
sucrose. Autoradiography for 
 
35
 
S-labeled SgII identified
the fractions containing either iLDCVs or mLDCVs, and
Western blotting identified those that contain VMAT2.
Wild-type VMAT2 colocalizes with labeled SgII in both i-
and mLDCV fractions (Fig. 5, A and B). In contrast, 507*
is barely detectable in mLDCV-containing fractions, but
colocalizes with labeled SgII in iLDCV-containing gradi-
ent fractions (Fig. 5, A and B). These iLDCV fractions do
not contain detectable amounts of other membranes, in-
cluding endosomes and SLMVs (Fig. 5 B), enabling us to
distinguish between the VMAT2 on iLDCVs and on other
membranes. To quantify these observations, we studied
three stable cell lines each for wild-type and 507* VMAT2,
and compared the amounts of protein on i- and mLDCVs.
Using autoradiography to identify the peak iLDCV and
mLDCV fractions, we determined the amount of VMAT2
in these fractions by densitometry and expressed the
amount in either iLDCVs or mLDCVs as a fraction of to-
tal VMAT2 in all peak fractions. The analysis shows that
more than half of wild-type VMAT2 in LDCVs localizes
to mLDCVs, whereas only a small fraction (
 
z
 
10%) of
507* resides on these membranes (Fig. 5 C). In contrast,
a substantially larger proportion of 507* localizes to
iLDCVs relative to wild-type VMAT2. The quantitation
of iLDCVs specifically excludes VMAT2 that does not
cofractionate with the peak of SgII, focusing on the pro-
tein in iLDCVs rather than that in endosomes or SLMVs.
A substantial proportion of the 507* that enters the regu-
lated secretory pathway thus appears to be removed from
LDCVs during maturation, indicating a role for the acidic
cluster in retention on mLDCVs.
Figure 3. 507* colocalizes with
TGN-38 by immunofluorescence.
PC12 cells stably expressing 507*
were double stained with the
mouse monoclonal antibody to
HA (b, h, and k) and polyclonal
antibodies to synaptophysin,
mannose-6-phosphate receptor
(M6PR), and TGN-38 (a, g, and
j), or with a rat monoclonal HA
antibody (e) and a mouse mono-
clonal antibody to transferrin
receptor (TfR) (d). Secondary
antibodies conjugated to Cy3 and
Cy5 were used to distinguish
between 507* and the marker
proteins, respectively. Merged
Cy3 and Cy5 images are shown in
c, f, i, and l. 507* does not colo-
calize with synaptophysin, TfR,
or M6PR, but does colocalize ex-
tensively with TGN-38. (Insets)
Perinuclear staining (arrow-
heads) at high magnification.
Bar, 10 mm. 
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The Role of Phosphorylation in VMAT2 Removal from 
Maturing LDCVs
 
Phosphorylation of the acidic cluster in VMAT2 may also
influence targeting to LDCVs. In the case of furin, re-
placement of phosphorylated serines within the cluster by
aspartate to mimic phosphorylation promotes retrieval
from LDCVs to the TGN. In contrast, replacement of
these serines by alanine to prevent phosphorylation pro-
motes localization to LDCVs (Jones et al., 1995; Dittie
et al., 1997). Since serines within the acidic cluster of
VMAT2 also undergo phosphorylation by casein kinase 2
(Krantz et al., 1997), we investigated the role of phos-
phorylation in VMAT2 trafficking to LDCVs by replacing
the serines with either alanine (AA mutant) or aspartate (DD
mutant). After stable expression of the two constructs in
PC12 cells, we compared their localization to SgII by im-
munofluorescence and density gradient fractionation. Like
wild-type VMAT2, the AA mutant colocalizes extensively
with SgII at the tips of neuritic processes, and appears at
low levels in the cell body (Fig. 6, a–c). By gradient frac-
tionation as well, wild-type and AA VMAT2 colocalize
with SgII (Fig. 7 B). The DD mutant also colocalizes with
SgII at the tips of processes and in heavy gradient fractions
(Figs. 6, d–f, and 7 C), but a significant proportion does
not colocalize with SgII. Rather, DD appears partially re-
distributed to a perinuclear compartment by immunofluo-
rescence and to membranes lighter than LDCVs by gradi-
ent fractionation (Figs. 6, d–f, and 7 C).
 
Localization of the DD mutant resembles that observed
for 507*, suggesting that DD may also undergo removal
from LDCVs. To address this possibility, we used the two-
step fractionation procedure to separate i- and mLDCVs.
By this analysis, the AA mutant strongly resembles wild-
type VMAT2, with more than half of the AA in the regu-
lated secretory pathway appearing on mLDCVs (Fig. 5 C).
In contrast, the localization of DD resembles that of 507*,
with reduced expression on mLDCVs. Of the DD mutant
sorted into LDCVs, only 
 
z
 
36% resides on mLDCVs (Fig. 5
C). Although the effect of the DD mutation on localization
to LDCVs appears less dramatic than that of the 507* dele-
tion, the proportion of DD on mLDCVs is clearly reduced
relative to AA (
 
z
 
64%) and wild-type VMAT2 (
 
z
 
56%).
Thus, phosphorylation of the acidic motif apparently influ-
ences the localization of VMAT2 to LDCVs by regulating
the removal of VMAT2 during LDCV maturation.
 
Binding to PACS-1
 
The AA and DD mutations in VMAT2 have effects very
similar to the analogous AA and DD mutations in furin.
In both cases, replacement of the serines by aspartate to
mimic phosphorylation promotes removal from iLDCVs,
whereas replacement by alanine to mimic dephosphoryla-
tion promotes retention on LDCVs. However, VMAT2
normally resides on LDCVs, whereas furin normally re-
sides in the TGN (Molloy et al., 1994; Jones et al., 1995;
Schafer et al., 1995). One possible explanation for this dis-
Figure 4. The 507* deletion lo-
calizes to a BFA-resistant com-
partment that cofractionates
with iLDCVs. (A) PC12 cells
stably expressing 507* were in-
cubated without or with 5 mg/ml
brefeldin A for 15 min, and then
double stained with mouse mono-
clonal HA antibody and rabbit
polyclonal TGN-38 antiserum,
followed by anti–mouse anti-
body conjugated to Cy3 and
anti–rabbit antibody conjugated
to Cy5. 507* and TGN-38 colo-
calize in the absence but not the
presence of BFA. As indicated
by the dispersion of TGN-38,
BFA causes fragmentation of
the TGN but not the compart-
ment containing 507*. (Insets)
Perinuclear staining (arrow-
heads) at high magnification.
Bar, 10 mm. (B) To label SgII in
the TGN, cells were incubated
for 5 min with 0.5 mCi/ml 35S-
sulfate, and then chilled on ice.
To allow the labeled SgII to en-
ter iLDCVs, cells were labeled
in the same way but incubated at
378C for an additional 15 min in
medium with unlabeled sulfate before harvesting. The resulting post-nuclear supernatants were then separated by velocity sedimenta-
tion through 0.3–1.2 M sucrose, and fractions collected from the top of the gradient. Labeled SgII was detected by autoradiography and
507* protein by Western analysis using the monoclonal HA antibody. 507* comigrates with iLDCVs in fractions 2–4 rather than with
the TGN in fractions 7–9. 
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crepancy is that the acidic clusters in the two proteins in-
teract with distinct cytosolic sorting machinery.
The cytoplasmic protein PACS-1 is considered to medi-
ate the retrieval of furin from LDCVs. PACS-1 binds to
the phosphorylated acidic cluster in furin and appears to
promote retrieval to the TGN through an interaction with
the clathrin adaptor protein AP-1 (Wan et al., 1998). To
determine whether VMAT2 also binds to PACS-1, we
produced GST fusion proteins containing the COOH ter-
mini of wild-type, AA, DD, and 507* VMAT2, and exam-
ined binding to a bacterially expressed domain of PACS-1
known to interact with furin (Wan et al., 1998). We first
compared PACS-1 binding to a GST fusion containing the
COOH terminus of wild-type VMAT2 that either was or
was not phosphorylated in vitro
 
 
 
by casein kinase 2. Very
similar to furin, PACS-1 binds more strongly to the phos-
phorylated than the unphosphorylated form of VMAT2
(Fig. 8). In addition, VMAT2 binds PACS-1 with an avid-
ity similar to furin, supporting the parallel between
VMAT2 and furin with respect to this interaction. We
then compared PACS-1 binding by wild-type, AA, and
DD COOH-terminal VMAT2 domains. As anticipated,
PACS-1 binds strongly to the COOH terminus of the DD
mutant and at very low levels to wild- type VMAT2 and
the other mutants (Fig. 8). Thus, PACS-1 binds specifically
and preferentially to the phosphorylated acidic cluster in
VMAT2. 
 
Discussion
 
The analysis of serial COOH-terminal truncations shows
that an acidic cluster at the distal COOH terminus of
VMAT2 influences localization to LDCVs. The sorting
motif includes six acidic residues and two serines previ-
ously shown to be phosphorylated by casein kinase 2
(Krantz et al., 1997). By both immunofluorescence and
gradient fractionation, deletion of these eight residues re-
duces VMAT2 expression on LDCVs. Phosphorylation of
the acidic cluster apparently has a similar effect on steady
state localization of the transporter. Replacement of
serines in the cluster by aspartate to mimic phosphoryla-
tion reduces localization of VMAT2 to LDCVs. In con-
 
Figure 5.
 
VMAT2 mutants 507* and DD localize preferentially
to immature rather than mature LDCVs. (A) Cells were labeled
with 0.2 mCi/ml 
 
35
 
S-sulfate for 6 h, incubated for an additional 12 h
with unlabeled sulfate, and PNS separated by velocity sedimenta-
tion through 0.3–1.2 M sucrose. Fractions containing mLDCVs
were identified by scintillation counting, pooled, and further sep-
arated by equilibrium sedimentation through 0.9–1.7 M sucrose.
The resulting fractions were collected from the top of the gradient
and either submitted to autoradiography to detect radiolabeled
SgII or subjected to Western analysis for HA to detect VMAT2.
The starting material (PNS) is shown to the right of the fractions.
Wild-type VMAT2 cofractionates with labeled SgII in mLDCVs
(fractions 9 and 10) and shows enrichment in these fractions rela-
tive to the PNS. 507* cofractionates with mLDCVs in fraction 9,
but is not enriched relative to the PNS. (B) Cells were labeled
with 0.5 mCi/ml 
 
35
 
S-sulfate for 5 min and incubated for an addi-
tional 15 min with unlabeled sulfate. After velocity sedimenta-
tion, the fractions containing iLDCVs were pooled and further
separated by equilibrium sedimentation as described in A, fol-
lowed by autoradiography for 
 
35
 
S-sulfate, Western analysis for
HA, 
 
g
 
-adaptin, transferrin receptor (TfR), and synaptophysin.
Both wild-type and 507* VMAT2 cofractionate with labeled SgII
in iLDCVs (fractions 7 and 8). Relative to the PNS, 507* is more
enriched in iLDCVs than mLDCVs (A). Light membranes such
as endosomes and SLMVs do not contaminate the iLDCV frac-
tions containing 
 
35
 
S-SgII. (C) For wt, 507*, AA, and DD VMAT2,
three stable cell lines were subjected to the two-step fractionation
procedure described above. Peak iLDCV and mLDCV fractions
were identified by autoradiography, and the amount of VMAT2
protein in these fractions was measured using NIH Image. The
amount of protein on i- and mLDCVs is expressed as a fraction of
the total VMAT2 immunoreactivity in all peak fractions. Only
the two peak LDCV fractions containing 
 
35
 
S-SgII were used to
determine the amount of VMAT2 expressed on i- or mLDCVs.
The bars indicate the mean 
 
6 
 
SEM (
 
n
 
 5 
 
3). 
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trast, replacement of the serines with alanine to prevent
phosphorylation does not perturb the localization of
VMAT2 to LDCVs.
Phosphorylation of an acidic cluster in furin reduces
LDCV expression by promoting removal during LDCV
maturation, and dephosphorylation blocks removal (Jones
et al., 1995; Dittie et al., 1997). We now show that the DD
mutation reduces VMAT2 expression on m- but not
iLDCVs, suggesting that phosphorylation also promotes
VMAT2 removal during LDCV maturation. In contrast,
the AA mutation that does not permit phosphorylation at
these sites does not substantially affect the proportion of
VMAT2 on m- versus iLDCVs. Thus, the data strongly
suggest that phosphorylation of the acidic cluster reduces
the localization of both VMAT2 and furin on LDCVs
by promoting their removal during LDCV maturation,
whereas dephosphorylation promotes the retention of
both proteins on LDCVs.
Although phosphorylation of an acidic cluster appears
to promote the removal of both VMAT2 and furin from
iLDCVs, VMAT2 normally localizes to LDCVs, whereas
furin localizes to the TGN. How can the same motif acting
on the same trafficking event contribute to such divergent
steady state localization? The acidic clusters in the two
proteins may interact with distinct sorting machinery.
PACS-1 mediates the retrieval of furin by binding to the
phosphorylated acidic cluster (Wan et al., 1998). Removal
of VMAT2 from LDCVs may be mediated by a different
PACS isoform or an entirely distinct protein interaction.
However, we have found that PACS-1 binds to VMAT2
and furin with apparently similar avidity. Further, PACS-1
binds preferentially to the phosphorylated form of the
acidic cluster in VMAT2, just as it does with furin.
Since the acidic motifs in VMAT2 and furin have similar
effects on subcellular location, influence the same trafficking
event, and interact with the same sorting machinery, differ-
ences in the state of phosphorylation appear to account for
the divergent steady state localization of these two proteins.
Phosphorylation by casein kinase 2 is often constitutive;
however, dephosphorylation of the acidic cluster in furin has
been shown to undergo regulation. Indeed, dephosphoryla-
tion by a specific isoform of protein phosphatase 2A regu-
lates the endocytic trafficking of furin (Molloy et al., 1998).
Our results now indicate that, just as the persistent phos-
phorylation of furin in LDCVs promotes its retrieval to the
TGN, dephosphorylation of the acidic cluster in VMAT2 ap-
pears to promote its retention on mLDCVs.
Previous work has suggested that PACS-1 mediates the
retrieval of furin from iLDCVs to the TGN. Consistent
with a role for retrieval in the steady state localization of
furin to the TGN, reduction of PACS-1 expression redis-
tributes furin out of the TGN (Wan et al., 1998). In addi-
tion, PACS-1 links furin to AP-1, a component of the
clathrin sorting machinery, and AP-1–dependent retrieval
from iLDCVs has been observed for several proteins, in-
cluding the mannose-6-phosphate receptor (Klumperman
et al., 1998). We now show that VMAT2 also binds to
PACS-1. However, the 507* mutant undergoes retrieval
from LDCVs even though it lacks the acidic cluster and
hence cannot interact with PACS-1. Indeed, 507* is ex-
cluded from mLDCVs to an even greater extent than the
DD mutant, which strongly binds PACS-1. Deletion of the
acidic cluster in furin redistributes the protein into endo-
somes but may not eliminate expression in the TGN
(Schafer et al., 1995), suggesting that the motif may not be
essential for retrieval from LDCVs. Thus, rather than pro-
moting retrieval, the acidic cluster appears to function as a
retention signal that prevents the removal of proteins from
LDCVs. Phosphorylation by casein kinase 2 and subse-
quent binding to PACS-1 presumably inhibit this retention
signal and hence promote removal. Conversely, regulated
dephosphorylation restores the function of the acidic clus-
ter as a retention signal. Removal from LDCVs may there-
fore represent a default pathway blocked by the acidic
cluster in its dephosphorylated state.
Where do the VMAT2 mutants (507* and DD) go after
removal from maturing LDCVs? Although the velocity
gradient suggests little expression in the TGN (Fig. 4), the
immunofluorescence shows colocalization with TGN38
and to a lesser extent with the late endosomal and lysoso-
mal proteins mannose 6 phosphate receptor and cathepsin
B. The mutants may therefore cycle repeatedly between
the TGN and iLDCVs, increasing the likelihood of diver-
sion to late endosomes and lysosomes. Supporting this
possibility, we have observed increased turnover of 507*
(
 
t
 
1/2
 
 
 
z 
 
4 h) relative to wild-type VMAT2 (
 
t
 
1/2
 
 
 
z 
 
7 h). Alter-
natively, the removal of 507* and DD mutants from ma-
turing LDCVs might increase their trafficking to the
constitutive secretory pathway and hence to SLMVs. Im-
munofluorescence and gradient fractionation indicate
Figure 6. AA and DD VMAT2
differ in the extent of colocaliza-
tion with SgII. PC12 cells stably
expressing AA or DD VMAT2
were double stained for HA using
secondary antibodies conjugated
to Cy3 (a and d) and for SgII us-
ing secondary antibodies conju-
gated to Cy5 (b and e). The cells
were then examined by confocal
microscopy. The merged Cy3 and
Cy5 images are shown in c and
f. The AA mutant colocalizes
strongly with SgII, primarily at
the tips of cell processes. The DD
mutant colocalizes with SgII in
the tips of processes, but also ex-
hibits strong perinuclear staining
(arrowheads). Bar, 10 mm. 
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some colocalization of 507* with synaptophysin (Figs. 3,
a–c, and 5 B). However, we have not observed any increased
expression of these mutants on SLMVs separated from
other membrane vesicles by glycerol velocity gradient
 
fractionation (Clift-O’Grady et al., 1990; Krantz, D.E., C.
Waites, R.H. Edwards, unpublished observations). In ad-
dition, we have not detected the constitutive delivery of
507* and DD mutants to the cell surface (data not shown).
In contrast to mutants defective in sorting to the regulated
secretory pathway, which internalize large amounts of HA
antibody from the medium due to their external HA
epitope and their constitutive delivery at the cell surface
(Waites, C., and R.H. Edwards, manuscript in prepara-
tion), wild-type, 507*, DD, and AA VMAT2 exhibit very
little uptake of the HA antibody. Thus, the COOH-termi-
nal acidic cluster appears to have little role in sorting to
the regulated secretory pathway in the TGN.
Since acidic residues upstream of the IL motif in
VMAT2 also contribute to localization on LDCVs, what is
the relationship between these residues and the more
COOH-terminal acidic cluster? The two motifs may both
be required for retention on LDCVs. However, acidic res-
idues upstream of the dileucine motif in other proteins
have been shown to promote internalization from the
plasma membrane (Pond et al., 1995; Dietrich et al., 1997),
suggesting that these residues would more likely promote
than inhibit VMAT2 removal from LDCVs. Alternatively,
the two glutamates upstream of the dileucine-like motif
may be required for another trafficking event such as sort-
ing in endosomes or the TGN.
VMAT2 sorts to synaptic vesicles and tubulovesicular
structures as well as LDCVs (Nirenberg et al., 1995, 1996,
1997), indicating the potential of acidic cluster phosphory-
lation to regulate the proportion of protein on these differ-
ent populations of neurosecretory vesicles. Since LDCVs
reside in the cell body and dendrites as well as the nerve
terminal, alterations in the expression of VMAT2 on LDCVs
have the potential to affect somatodendritic release. LDCVs
also differ from SVs and other secretory vesicles in their re-
sponsiveness to different stimuli, and in the rate of release
Figure 7. Density gradient fractionation of AA and DD
VMAT2. Post-nuclear supernatants from PC12 cells stably ex-
pressing HA-tagged wild-type (A), AA (B), and DD (C)
VMAT2 were separated by equilibrium gradient centrifugation
through 0.6–1.6 M sucrose and the fractions analyzed by Western
blotting for HA (A–C, top), and SgII (bottom). The gradients
shown were then quantified using NIH Image and the amount of
VMAT2 and SgII expressed as a fraction of the total immunore-
activity. Wild-type and AA VMAT2 cofractionate with SgII in
heavy fractions. DD also cofractionates with SgII, but has a sec-
ond peak in lighter fractions. The analysis of three different sta-
ble cell lines for each construct yielded similar results.
Figure 8. PACS-1 binding to
the VMAT2 COOH termi-
nus. (A) GST fusion proteins
containing the COOH termi-
nus of wild-type VMAT2 or
furin were bound to glu-
tathione-sepharose beads and
phosphorylated  using casein
kinase 2. Unphosphorylated
and phosphorylated fusion
proteins bound to gluta-
thione-sepharose were then
incubated with a poly-His–
tagged version of the PACS-1
furin-binding domain and the
bound protein detected using an antipolyhistidine antibody
(PACS-1). Autoradiography was used to assess protein phosphor-
ylation (32P). Western analysis for GST confirmed the presence
of equal amounts of unphosphorylated and phosphorylated GST
fusion proteins. Similar to phosphorylated furin, phosphorylated
VMAT2 binds PACS-1 more strongly than the unphosphorylated
protein. (B) GST fusion proteins containing the COOH termini
of wild-type, AA, DD, or 507* VMAT2 were incubated with the
furin-binding domain of PACS-1 as described in A. Western anal-
ysis was then used as described above to detect bound PACS-1
and confirm the presence of equal amounts of GST fusions.
PACS-1 binds strongly to the DD mutant, but poorly to wild-type
VMAT2 and the AA mutant. 
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(Bruns and Jahn, 1995). The regulation of VMAT2 phos-
phorylation on its acidic cluster may thus influence the site,
mode, and hence the role of monoamines in signaling.
In summary, VMAT2 resembles furin with respect to
the influence of phosphorylation on membrane trafficking
and on binding to PACS-1, but VMAT2 differs in steady
state location. Differences in phosphorylation state appar-
ently confer the differences in subcellular distribution by
regulating removal from LDCVs. In addition, the acidic
motif in VMAT2 acts as a retention signal that is inacti-
vated by phosphorylation, rather than as a positive signal
for removal from LDCVs. The motif may thus interact in
its unphosphorylated state with a protein that retains
VMAT2 on LDCVs. Phosphorylation may displace this
protein, promoting an interaction with PACS and removal
from LDCVs. A large number of membrane proteins in-
cluding the synaptic vesicle protein synaptotagmin as well
as furin and VMAT2 contain acidic motifs phosphorylated
by casein kinase (Bennett et al., 1993; Molloy et al., 1999).
The mechanism of regulated retention may therefore act
at multiple trafficking events to influence the subcellular
distribution and physiological role of many proteins.
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